Previous 10 | Next 10 |
Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19 host genome structur...
Mesoblast (MESO) announces additional results from the DREAM-HF Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR) or control sham.A single dose of rexlemestrocel-L resulted in subst...
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chro...
Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...
I had high hopes for Mesoblast's revolutionary therapy after the ODAC thumbs up, and said so in my previous coverage. However, the FDA's rejection of the NDA, and request for a new trial, makes Mesoblast's future look bleak in the USA. I still believe they should be granted accele...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks snapped their three-day advance with small losses Friday in volatile quadruple witching trading, as progress stalled on a COVID financ...
Shares of biotech company Mesoblast Limited (NASDAQ: MESO) tanked on Friday after the company released discouraging news regarding the clinical trials of its COVID-19 treatment. As of 3:30 p.m. EST, the stock was down a painful 33% for the day. And it's now tumbled a whopping 54% fr...
Gainers: CURO Group (CURO) +78%.Mereo BioPharma (MREO) +49%.Cyclo Therapeutics (CYTH) +42%.China Green Agriculture (CGA) +30%.Origin Agritech (SEED) +23%.Upstart (UPST) +22%.AgEagle Aerial Systems (UAVS) +22%.Elys Game Technology (ELYS) +22%.Organovo (ONVO) +21%.Aqua Metals (AQMS) +...
Gainers: Mereo BioPharma (MREO) +91%, Cyclo Therapeutics (CYTH) +44%, Petros Pharmaceuticals (PTPI) +29%, CNS Pharmaceuticals (CNSP) +17%, Humanigen (HGEN) +17%.Losers: Mesoblast (MESO) -34%, Virios Therapeutics (VIRI) -30%, BioCardia (BCDA) -...
Mesoblast (MESO) -31% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19.Wunong Net Technology Company (WNW) -18%.Applied DNA Sciences (APDN) -16% on Q4 earnings release.Takung Art (TKAT) -14%.Virgin Galactic Holdings (SPCE) -11%&...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...